8:31 AM ET
8-K
Licensing Deal
Ocugen Licensing Deal with Celairis Therapeutics Holdings Pty Ltd Worth $7.1M
Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.
- Value
- $7.1M
- Counterparty
- Celairis Therapeutics Holdings Pty Ltd
- Term
- 20 years